Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allozyne Inc.

This article was originally published in Start Up

Executive Summary

Allozyne Inc.'s novel interferon beta drug candidate is now in Phase I clinical trials for MS. The company used its proprietary linker technology to attach PEG to interferon, and believes that will allow more drug to be loaded into a dose and lead to a product that could be injected as infrequently as once per month. Moreover, it thinks its PEG conjugate should reduce tolerance problems and improve half-life over current interferons.

You may also be interested in...



Receptos Inc.

Receptos isn't the only company in the G-coupled protein receptor oral MS drug arena, but it believes its proprietary S1P1 agonist will improve on Novartis' first-in-class S1P1 modulator Gilenya. Unlike Gilenya, which hits four of the five S1P receptor subtypes, the Receptos molecule binds selectively to S1P1 and has a predicted human half-life of approximately one day, potentially improving the safety profile and reducing complications for MS patients.

Emerging MS Treatments: Reading the Gilenya Tea Leaves

The closely watched launch of Gilenya, the first oral treatment for multiple sclerosis, may have changed the game for developing new therapies for the disease. Start-Up profiles four emerging MS drug developers: Allozyne, GeNeuro, Nuron Biotech and Receptos.

Nuron Biotech Inc.

Founded by veterans of Pfizer, Nuron Biotech Inc. is developing a recombinant human interferon beta-1 free of human serum albumin and the aggregates that set off an immune response. Thus the start-up's lead candidate should not lose effectiveness or have the tolerability issues that plague existing interferon beta drugs. The company will move its agent directly into Phase III clinical trials in Europe this year.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel